$SLN

Silence Therapeutics (SLN) presented updates on its lead drug, divesiran, at the Cantor Fitzgerald Global Healthcare Conference. Phase II data showed strong response rates in polycythemia vera, with 90% at 6 mg every 6 weeks and 88% at 6 mg every 12 weeks. The company raised $200 million, ending Q2 with $72 million in cash, providing a 2.5-3 year runway. Management is preparing for Phase III discussions and weighing partnership options amid rising competition. SLN also highlighted other pipeline

Investing.com, citing Macquarie data for the week ended Aug. 14, reports global biotech funding up 75% year over year. IPOs rose 224% and follow-ons 140%, while private investment in public equity rose 29% and venture funding 38%. Examples include Jazz Pharmaceuticals’ $820M upfront deal for Actio Bio and Silence Therapeutics’ $200M upsized IPO.

Silence Therapeutics plc (Nasdaq: SLN) said it closed an underwritten public offering of 14,907,407 American Depositary Shares at $13.50 per ADS, including full exercise of the underwriters’ option for 1,944,444 additional ADSs. Gross proceeds were about $201.3 million before fees. Joint book-runners were Jefferies, Morgan Stanley, Cantor and William Blair.

Silence Therapeutics plc (Nasdaq: SLN) said it closed an upsized underwritten public offering of 14,907,407 ADSs at $13.50 per ADS, with underwriters fully exercising their option for 1,944,444 additional ADSs. Gross proceeds were about $201.3 million before fees. Jefferies, Morgan Stanley, Cantor and William Blair managed the deal.

Richard Griffiths filed Amendment No. 11 reporting beneficial ownership of 14,391,498 Silence Therapeutics plc ordinary shares, or 7.97% of the class, based on 180,628,068 shares outstanding. Holdings include ADSs via Ora Capital Limited and Cream Capital Limited plus direct shares. The filing cites dilution from share capital increases and open-market ADS sales, including 5,484,320 ADSs sold Aug 10-12, 2026 for $87 proceeds.

Silence Therapeutics plc (SLN) reported Schedule 13G ownership updates. Invus Public Equities, L.P. held 8,707,287 ordinary shares (2,902,429 ADSs), or 6.1% of the class as of June 30, 2026. Avicenna Life Sci Master Fund LP held 1,227,027 shares (409,009 ADSs), or 0.9%. Raymond Debbane may be deemed to own 9,934,314 shares (7.0%) via controlled entities.

Silence Therapeutics plc launched an underwritten U.S. ADS offering of about $150m, priced at $13.50 per ADS for 12,962,963 ADS, targeting gross proceeds of about $175m. AbCellera Biologics commenced a $200m underwritten common share offering. Beyang Therapeutics raised nearly $30m Series A, and Remepy closed a $36m Series A to fund Phase III Hybridopa.

Silence Therapeutics plc (SLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares 2026-08-10 LONDON—(BUSINESS WIRE)—Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfe

Silence Therapeutics (SLN) shares fell 1.8% in pre-open after the company priced an underwritten public offering of about 12.96M ADS at $13.50, targeting about $175M gross proceeds, with an option for underwriters to buy up to 1.94M more ADS. The move followed positive Phase 2 SANRECO topline results for divesiran and a Q2 2026 net loss of $0.09 per share.

Silence Therapeutics, a UK biotech, priced a $175 million offering in the US, according to the report. The piece also notes that European equities traded in the US as American Depositary Receipts rose in Tuesday trading. The offering size may affect dilution and near-term liquidity for investors.